Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2013

01-12-2013 | Research Article

Geographic location of antiretroviral clinical trials in HIV infected pediatric patients

Authors: Katie J. Suda, Jodie Greene, Chasity M. Shelton

Published in: International Journal of Clinical Pharmacy | Issue 6/2013

Login to get access

Abstract

Background Some medicines regulatory authorities are encouraging research in pediatrics. However, children are a vulnerable population, and previous studies have suggested that research is increasingly being conducted outside of developed countries. Objective The purpose of this study is to determine the location of trials in the pediatric population with human immunodeficiency virus (HIV). Setting Not applicable. Methods Clinical trials registered in the largest international clinical trials registry (clinicaltrials.gov) evaluating antiretrovirals in pediatric HIV infected patients were included. Data were collected on the location, funding, study purpose, design, initiation date, age of subjects, and medication classes tested. Main outcome measures We assessed frequencies of characteristics of pediatric HIV trials registered in the clinicaltrials.gov database. Results Overall, 288 studies were included in the analysis. Most trials were conducted in ages 12–17 years (83 %), followed by studies in those <6 years (25 %) and 6–11 years (21 %). The location of most trials included at least one site in developed countries (83 %). The number of trials completed exclusively in developing countries increased from 1989 to 2011. Conclusions The majority of pediatric antiretroviral trials registered in clinicaltrials.gov were conducted in adolescent subjects in developed countries. The number of pediatric HIV studies in developing countries increased while studies conducted in developed countries decreased similar to trends of HIV.
Literature
1.
go back to reference Christensen ML, Helms RA, Chesney RW. Is pediatric labeling really necessary? Pediatrics. 1999;104(3 Pt 2):593–7.PubMed Christensen ML, Helms RA, Chesney RW. Is pediatric labeling really necessary? Pediatrics. 1999;104(3 Pt 2):593–7.PubMed
2.
go back to reference Blumer JL. Off-label uses of drugs in children. Pediatrics. 1999;104(3 Pt 2):598–602.PubMed Blumer JL. Off-label uses of drugs in children. Pediatrics. 1999;104(3 Pt 2):598–602.PubMed
3.
go back to reference Tabor E. FDA requirements for clinical studies in pediatric patients. Regul Focus. 2009;14:16–21. Tabor E. FDA requirements for clinical studies in pediatric patients. Regul Focus. 2009;14:16–21.
5.
go back to reference Glickman SW, McHutchinson JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816–23.PubMedCrossRef Glickman SW, McHutchinson JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816–23.PubMedCrossRef
7.
go back to reference Klitzman RL, Kleinert K, Rifai-Bashjawish H, Leu CS. The reporting of IRB review in journal articles presenting HIV research conducted in the developing world. Dev World Bioeth. 2011;11:161–9.PubMedCrossRef Klitzman RL, Kleinert K, Rifai-Bashjawish H, Leu CS. The reporting of IRB review in journal articles presenting HIV research conducted in the developing world. Dev World Bioeth. 2011;11:161–9.PubMedCrossRef
8.
go back to reference Pasquali SK, Burstein DS, Benjamin DK Jr, Smith PB, Li JS. Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics. 2010;126:e687–92.PubMedCrossRef Pasquali SK, Burstein DS, Benjamin DK Jr, Smith PB, Li JS. Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics. 2010;126:e687–92.PubMedCrossRef
9.
go back to reference World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva, Switzerland; World Health Organization; 2011;18, 23, 24. ISBN 978 92 4 150298 6. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva, Switzerland; World Health Organization; 2011;18, 23, 24. ISBN 978 92 4 150298 6.
15.
go back to reference Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors [Internet]. [Place unknown]: ICMJE; 2004 [cited 2013 April 10]. Available from: http://www.icmje.org/clin_trial.pdf. Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors [Internet]. [Place unknown]: ICMJE; 2004 [cited 2013 April 10]. Available from: http://​www.​icmje.​org/​clin_​trial.​pdf.
17.
go back to reference Huser V, Cimino JJ. Evaluation adherence to the International Committee of Medical Journal Editors’ policy of mandatory, timely clinical trial registration. J Am Med Inform Assoc. 2013;0:1–6. Huser V, Cimino JJ. Evaluation adherence to the International Committee of Medical Journal Editors’ policy of mandatory, timely clinical trial registration. J Am Med Inform Assoc. 2013;0:1–6.
Metadata
Title
Geographic location of antiretroviral clinical trials in HIV infected pediatric patients
Authors
Katie J. Suda
Jodie Greene
Chasity M. Shelton
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9849-x

Other articles of this Issue 6/2013

International Journal of Clinical Pharmacy 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.